Small cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma.
Despite over 30 years of clinical research, little progress has been made in the management …

Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower
pace than non–small-cell lung cancer. In fact, the standard treatment regimen for limited …

Purpose Several sentinel phase III randomized trials have recently been published
challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC) …

Background Small cell lung cancer (SCLC) is a lethal disease for which there have been
only small advances in diagnosis and treatment in the past decade. Our goal was to revise …

Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …

Purpose In lung cancer, randomized trials assessing hyperfractionated or accelerated
radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or …

Learning Objectives After completing this course, the reader will be able to: Discuss the
currently available SCLC treatment options. Describe the benefits of integrating thoracic …

Although small-cell lung cancer (SCLC) makes up a smaller proportion of all lung cancers
than it did 25 years ago, it remains a common cause of cancer mortality that requires more …

Widening indications for combining radiation therapy with cytotoxic or molecular-targeted
drugs have mainly been driven by pragmatic clinical trials. With a flurry of novel drugs in …

Qualitätsindikatoren wurden durch Sens et al. wie folgt definiert:„Ein Indikator ist ein
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …